Get the Stockscreener App
32.26
1.50%
-0.49
Ionis Pharmaceuticals Inc stock is traded at $32.26, with a volume of 946.93K.
It is down -1.50% in the last 24 hours and up +16.17% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
See More
Previous Close:
$32.75
Open:
$32.77
24h Volume:
946.93K
Relative Volume:
0.55
Market Cap:
$5.22B
Revenue:
$705.14M
Net Income/Loss:
$-453.90M
P/E Ratio:
-10.61
EPS:
-3.04
Net Cash Flow:
$-551.29M
1W Performance:
-1.59%
1M Performance:
+16.17%
6M Performance:
-17.68%
1Y Performance:
-18.27%
1-Day Range:
$32.26
$33.64
1-Week Range:
$31.66
$33.98
52-Week Range:
$23.95
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
32.26 | 5.22B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-25 | Initiated | H.C. Wainwright | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Bennett C. Frank of Ionis Pharmaceuticals sells $222,113 in stock - MSN
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Ionis to host 2025 virtual Annual Meeting of Stockholders | IONS Stock News - GuruFocus
Ionis to host 2025 virtual Annual Meeting of Stockholders - Quantisnow
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Spinocerebellar Ataxias Pipeline 2025: Comprehensive - openPR.com
Oligonucleotide Delivery System Market Key Players Analysis - openPR.com
Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts - Yahoo Finance
Ionis Pharmaceuticals targets $750M revenue for 2025 with multiple launches underway - MSN
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View - MSN
Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Analysts Just Shipped A Substantial Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Estimates - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Earnings call transcript: Ionis Pharmaceuticals beats Q1 2025 forecasts - Investing.com Australia
Ionis Pharmaceuticals (IONS) Projects Revenue Growth with TRYNGO - GuruFocus
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates - MSN
IONIS: Guggenheim Maintains Buy Rating but Lowers Price Target | - GuruFocus
Ionis Pharmaceuticals (IONS) Receives Price Target Boost from HC Wainwright | IONS Stock News - GuruFocus
Ionis Pharmaceuticals (IONS) Target Price Adjusted by Guggenheim - GuruFocus
Polycythemia vera Market: Epidemiology, Therapies, - openPR.com
Ionis Earnings: Strong Commercial Launch of Tryngolza; Positive Long-Term Outlook - Morningstar
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 13 Experts - Benzinga
Ionis Pharmaceuticals (IONS) Target Price Increased to $50 After Strong Q1 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals Ups Revenue Forecast After Q1 Success - Finimize
Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says - marketscreener.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2025 Earnings Call Transcript - Insider Monkey
Ionis Pharmaceuticals (IONS) Target Price Adjusted by Guggenheim | IONS Stock News - GuruFocus
Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlight - GuruFocus
Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Ionis Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Ionis Pharmaceuticals: Q1 Earnings Snapshot - MySA
Ionis Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges - TipRanks
Ionis Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Ionis Pharmaceuticals (IONS) Boosts 2025 Revenue Guidance and St - GuruFocus
Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge - Benzinga
Earnings call transcript: Ionis Pharmaceuticals beats Q1 2025 forecasts By Investing.com - Investing.com India
Novartis to acquire Regulus in deal for kidney disease drug - BioPharma Dive
Ionis Pharmaceuticals (IONS) Q1 2025 Earnings: Revenue Surpasses - GuruFocus
Ionis Pharmaceuticals Reports First Quarter 2025 Financial Results - TradingView
Ionis Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Ionis Pharmaceuticals Q1 Net Loss Narrows as Revenue Increases; 2025 Revenue Guidance Raised - marketscreener.com
Ionis (IONS) Sees Strong Q1 Revenue with New Launches Fueling Gr - GuruFocus
Ionis reports first quarter 2025 financial results - BioSpace
IONIS PHARMACEUTICALS Earnings Results: $IONS Reports Quarterly Earnings - Nasdaq
Ionis reports first quarter 2025 financial results | IONS Stock News - GuruFocus
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ionis Pharmaceuticals Inc Stock (IONS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Birchler Brian | EVP, Corp and Development Ops |
Apr 15 '25 |
Option Exercise |
0.00 |
1,875 |
0 |
57,340 |
| Birchler Brian | EVP, Corp and Development Ops |
Apr 16 '25 |
Sale |
28.37 |
680 |
19,292 |
56,660 |
| Jenne Kyle | EVP, Chf GL Pdt Str Ofcr |
Apr 15 '25 |
Option Exercise |
0.00 |
12,226 |
0 |
14,215 |
| Jenne Kyle | EVP, Chf GL Pdt Str Ofcr |
Apr 16 '25 |
Sale |
28.36 |
3,016 |
85,534 |
11,199 |
| Baroldi Joseph | EVP, Chief Business Officer |
Apr 15 '25 |
Option Exercise |
0.00 |
10,837 |
0 |
35,854 |
| Baroldi Joseph | EVP, Chief Business Officer |
Apr 16 '25 |
Sale |
28.40 |
3,928 |
111,555 |
31,926 |
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):